Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Percutaneous aortic valvuloplasty.

M E Alcaino1, R Smith, R M Allan

  • 1Department of Cardiovascular Medicine, Prince Henry Hospital, NSW.

The Medical Journal of Australia
|January 20, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prospective randomised blinded clinical trial assessing effectiveness of three dental plaque control methods in dogs.

The Journal of small animal practice·2018
Same author

Bilateral flexural deformity in a six-week-old kitten.

The Journal of small animal practice·2017
Same author

A modified Maquet technique for management of cranial cruciate avulsion in a cat.

The Journal of small animal practice·2013
Same author

Model selection and population size using capture-recapture methods.

Journal of clinical epidemiology·1999
Same author

Impact of an aggressive stenting strategy on initial and one-year follow-up costs in patients undergoing coronary angioplasty.

Australian and New Zealand journal of medicine·1999
Same author

Percutaneous transseptal mitral valvotomy--progress report.

Australian and New Zealand journal of medicine·1999
Same journal

Still Treating Yesterday's Risk? Reconsidering Antiviral Use for Mild-to-Moderate COVID-19 Cases in a Broadly Immune Population.

The Medical journal of Australia·2026
Same journal

Striving for Racial Equity in Oral Cancer Research: A Case Study.

The Medical journal of Australia·2026
Same journal

Progressing Cross-Sector Collaboration for People With Eating Disorders and Higher Weight: Priority Actions From an Expert Roundtable Using a Modified Nominal Group Technique.

The Medical journal of Australia·2026
Same journal

Self-Poisoning With Prazosin and Its Off-Label Use in Australia, 2014-2024: Analysis of NSW Poisons Information Centre Data.

The Medical journal of Australia·2026
Same journal

Drivers of Vaccine Uptake for Aboriginal and Torres Strait Islander Children to Inform Tailored Strategies: A Qualitative Study Exploring Health Service Provider Perspective.

The Medical journal of Australia·2026
Same journal

Four Urgent Actions for the Rights to Culturally Safe Breastfeeding for Aboriginal and Torres Strait Islander Mothers and Babies to Breastfeed in Neonatal Intensive Care Environments.

The Medical journal of Australia·2026
See all related articles

Percutaneous aortic valvuloplasty (PAV) offers palliative relief for severe aortic stenosis in non-surgical candidates. While complications occur, PAV improves symptoms and valve function in selected patients.

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Severe aortic stenosis poses significant risks, especially for patients ineligible for surgical aortic valve replacement.
  • Palliative treatment options are crucial for improving quality of life in this high-risk population.

Purpose of the Study:

  • To evaluate the short-term and long-term outcomes of percutaneous transluminal aortic valvuloplasty (PTAV) in patients with severe aortic stenosis.
  • To assess the safety and efficacy of PTAV as a palliative procedure.

Main Methods:

  • A retrospective follow-up study was conducted involving 18 patients (mean age 79 years) with severe aortic stenosis who were not candidates for surgery.
  • Percutaneous transluminal aortic valvuloplasty (PTAV) was performed using balloon catheter techniques.

Related Experiment Videos

  • Patient survival and symptomatic status were the primary outcome measures.

    • Main Results:

    • PTAV significantly reduced the aortic valve pressure gradient (64.8 to 38 mmHg) and increased aortic valve area (0.4 to 0.6 cm²).
    • Fifteen patients showed early symptomatic improvement (NYHA class), though seven experienced complications, including two deaths.
    • Long-term follow-up (mean 13.3 months) revealed sustained improvement in six patients, with seven deaths (three cardiac, four non-cardiac).

    Conclusions:

    • Percutaneous transluminal aortic valvuloplasty (PTAV) serves as a valuable palliative option for carefully selected patients with severe aortic stenosis who cannot undergo aortic valve replacement.
    • PTAV can improve hemodynamic parameters and functional status, offering a potential benefit in high-risk individuals.